ChitogenX Inc.

Equities

CHGX

CA1699161032

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 20:09:15 15/07/2024 BST			5-day change	1st Jan Change
0.03 ^CAD	0.00%		-33.33%	-53.85%

07-02	ChitogenX Inc. Reports Earnings Results for the First Quarter Ended April 30, 2024	CI
05-27	ChitogenX Inc. Reports Earnings Results for the Full Year Ended January 31, 2024	CI

ChitogenX Inc. Reports Earnings Results for the First Quarter Ended April 30, 2024

July 02, 2024 at 12:11 pm

ChitogenX Inc. reported earnings results for the first quarter ended April 30, 2024. For the first quarter, the company reported net loss was CAD 0.157 million compared to net income of CAD 0.097 million a year ago.

Latest news about ChitogenX Inc.

ChitogenX Inc. Reports Earnings Results for the First Quarter Ended April 30, 2024	07-02	CI
ChitogenX Inc. Reports Earnings Results for the Full Year Ended January 31, 2024	05-27	CI
Chitogenxinc. Announces Resignation of Philippe Deschamps from the Board of Directors	02-27	CI
Chitogenx Inc. Announces CEO Changes	02-27	CI
ChitogenX Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2023	01-02	CI
Chitogenx Inc. Demonstrates ORTHO-R Efficacy and Osteoarthritidevelopment in Large Animal Study	11-09	CI
ChitogenX Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2023	29/09/23	CI
ChitogenX Inc. Receives Notice of Allowance for Key Patent in United States and Canada	28/09/23	CI
ChitogenX Concluded Enrolment For Its U.S. Multi-site Rotator Cuff Tear Repair Phase I/II Clinical Trial	26/09/23	MT
Chitogenx Concludes Enrolment for Its U.S. Phase I/II Rotator Cuff Tear Repair Clinical Trial	26/09/23	CI
ChitogenX Reports Q1 Results	30/06/23	MT
ChitogenX Inc. Reports Earnings Results for the First Quarter Ended April 30, 2023	29/06/23	CI
ChitogenX Inc. announced that it has received CAD 1.30825 million in funding	04/06/23	CI
ChitogenX Inc. Reports Earnings Results for the Full Year Ended January 31, 2023	31/05/23	CI
ChitogenX Inc. Auditor Raises 'Going Concern' Doubt	30/05/23	CI
ChitogenX Completes Non-Brokered Private Placement	05/05/23	MT
ChitogenX Inc. announced that it has received CAD 3.856348 million in funding	04/05/23	CI
ChitogenX Inc. announced that it expects to receive CAD 2.5 million in funding	03/04/23	CI
ChitogenX Inc. announced that it has received CAD 6.1 million in funding	27/02/23	CI
ChitogenX Inc. Demonstrates Ortho-R Residency Properties in Meniscus Study	14/02/23	CI
ChitogenX Inc. announced that it expects to receive CAD 6.1 million in funding	08/02/23	CI
ChitogenX Reports Loss for Fiscal Q3, Higher Expenses	29/12/22	MT
ChitogenX Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2022	28/12/22	CI
ChitogenX Completes Phase I/II ORTHO-R Rotator Cuff Tear Repair Clinical Trial	09/11/22	MT
Chitogenx Successfully Completes Initial Portion of Its U.S. Phase I/Ii Rotator Cuff Repair Clinical Trial	09/11/22	CI

Chart ChitogenX Inc.

Duration

Period

More charts

Company Profile

ChitogenX Inc. is a Canada-based emerging orthopedic and sports medicine biologics company. The Company is engaged in the development of therapeutic soft tissue repair technologies to improve the success rate of orthopedic and sports medicine surgeries. The Companyâs proprietary biopolymer has been specifically designed to increase the healing rates of occupational and sports related injuries to tendons, ligaments, meniscus and cartilage. The biopolymer, autologous platelet-rich plasma (PRP) combination implant, can be directly placed into the site of injuries by surgeons during routine operative procedures without significantly extending the duration of surgeries and without further interventions. The Company assess its potential for therapeutic uses outside of the soft tissue repair market. The Company, through Ecole Polytechnique and two industrial partners, delineates the PRP components, the distinct impact of each component and their collective action towards tissue repair.

Sector

Biotechnology & Medical Research

Calendar

18/07/2024 - Annual General Meeting

More about the company

	1st Jan change	Capi.
CHITOGENX INC.	-53.85%	1.83M
MODERNA, INC.	+25.83%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	+0.69%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	32.4B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.52B
MEDPACE HOLDINGS, INC.	+49.18%	13.74B
BIO-TECHNE CORPORATION	+3.45%	12.17B

Other Biotechnology & Medical Research

ChitogenX Inc.

Equities

CHGX

CA1699161032

Biotechnology & Medical Research

ChitogenX Inc. Reports Earnings Results for the First Quarter Ended April 30, 2024

Latest news about ChitogenX Inc.

Chart ChitogenX Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research